Ovarian Cancer Drugs Market Size, Trends, Report & Forecast 2027

Summary

Report Description

The global ovarian cancer drugs market is anticipated to witness an impressive growth during the forecast period, 2023-2027. Ovarian Cancer is one of the most severe and common cancer that affects the women these days. The ovaries in this malignancy undergo irregular cell proliferation, which can invade or negatively impact other body parts like the liver, lymph nodes, intestine and bladder linings, abdominal layers, and lymph nodes. The early stages of ovarian cancer are accompanied by a few indistinct symptoms that become more obvious as the malignancy progresses. These signs include bloating, pelvic pain, abdominal swell, and appetite loss. Ovarian Cancer risk is higher in women who have ovulated more frequently throughout their life, which can also include women who have never given birth and those who started ovulating at a young age. According to the American Cancer Society estimations, the inherited genetic factors contribute to about 10% of occurrences of ovarian cancer. 50% of women who carry BRCA1 or BRCA2 gene mutations will get breast or ovarian cancer. The most frequent type of ovarian cancer, accounting for 95% of occurrences worldwide, is ovarian carcinoma.

Growing Prevalence of Ovarian Cancer

The market for ovarian cancer drugs is growing in a highly favourable environment due to the recent increase in ovarian cancer cases. The American Cancer Society reports that in 2016, there were approximately 22,280 new instances of ovarian cancer diagnosed, resulting in 14,240 fatalities in the United States. Ovarian cancer accounted for 1.3% of the incidence rate and 2.4% of all fatalities attributable to cancer in 2016, according to statistics from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. There will be 23,820 new cases of ovarian cancer recorded in 2020, and the American Cancer Society believes that 1 in 75 women will get ovarian cancer during their lifetimes, with a 1 in 100 risks that she will pass away from it. As of 2017, 1,580 new ovarian cancer cases are anticipated to have been detected, making about 2.5% of all new cancer cases in the nation, according to the Australian Government's Cancer Australia. 1,047 fatalities are anticipated because of this in 2017. Therefore, it is anticipated that the ovarian cancer drugs sector will soon experience significant growth in developed nations.

Increasing Elderly Female Population

The increase in the percentage of the elderly female population is expected to boost the global ovarian cancer drugs market during the forecast period. As the population of old females increases, they are projected to be suffering from more gynecological problems. For instance, according to the World Population Prospects, there were about 9.5% females above the age group of 60 years as of 2021, from which most of the female population are susceptible to gynecological infections or diseases or cancer. Ovarian cancer prevalence is often low in women under the age of 40. Most of the ovarian cancer cases are observed among women 60 years of age and older, according to the American Cancer Society. 7,378 new cases of ovarian cancer were reported in the nation in 2014, with approximately 53% of those cases being identified in women 65 years of age and older, according to Cancer Research UK.

Increasing Research & Development Activities to Develop Ovarian Cancer Drugs

The growing prevalence of ovarian cancer has made the companies operating in the market along with different research organizations to increase their research & development activities in order to develop a potential drug treatment for ovarian cancer. Companies in the pharmaceutical business are increasingly coming up with novel drug combinations to treat ovarian cancer. To treat complex medical diseases, combination medications combine two or more active pharmaceutical ingredients (APIs) into a single dosage form. To lower manufacturing costs, boost compliance and efficiency, enhance medication concordance, increase profitability, and lessen side effects, pharmaceutical companies in the ovarian cancer medications market are investing in the research and development of novel products such as combination drugs. For instance, Roche's well-known tranquilizer Avastin (bevacizumab), which is used to treat advanced stage (III or IV) ovarian cancer, is a combination drug approved by the FDA that contains ingredients like carboplatin and paclitaxel.

DOWNLOAD FREE SAMPLE REPORT

Market Segmentation

The global ovarian cancer drugs market is segmented into by drug class, by tumor type, by distribution, by region. Based on by drug class, the market can be fragmented into alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, antineoplastics and others. Based on tumor type, the market can be categorized into epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor. Based on distribution channel, the market can be fragmented into hospital pharmacies, retail pharmacies, online pharmacies. Regionally, North America dominated the market among Europe, Asia Pacific, Middle East & Africa and South America. The United States held the biggest market in North America region and is expected to be a lucrative market in the forecast period as the government is investing in research for new drugs for the easy detection of ovarian cancer for the affected people.

Market Players

AstraZeneca, Plc., GlaxoSmithKline, Plc., Merck & Co., Clovis Oncology, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn Ko. KG, Novartis AG are some of the leading players operating in the global ovarian cancer drugs market.

Attribute	Details
Base Year	2021
Historic Data	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027
Report coverage	Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends
Segments covered	· By Drug Class · By Tumor Type · By Distribution Channel · By Region
Regional scope	North America; Asia Pacific; Europe; South America; Middle East & Africa
Country scope	United States; Canada; Mexico; India; Japan; South Korea; Australia; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE
Key companies profiled	AstraZeneca, Plc., GlaxoSmithKline, Plc., Merck & Co., Clovis Oncology, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn Ko. KG, Novartis AG
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global ovarian cancer drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Ovarian Cancer Drugs Market, By Drug Class:

o Alkylating Agents

o Mitotic Inhibitors

o Antirheumatics

o Antipsoriatics

o VEGF/VEGFR Inhibitors

o PARP Inhibitors

o Antineoplastics

o Others

Ovarian Cancer Drugs Market, By Tumor Type:

o Epithelial Ovarian Cancer

o Ovarian Low Malignant Potential Tumor

o Germ Cell Tumor

o Sex Cord-Stromal Tumor

· Ovarian Cancer Drugs Market, By Distribution Channel:

o Hospital Pharmacies

o Retail Pharmacies

o Online Pharmacies

Ovarian Cancer Drugs Market, By Region:

North America

United States
Canada
Mexico

Europe

Germany
France
United Kingdom
Spain
Italy

Asia Pacific

China
India
Japan
South Korea
Australia

South America

Brazil
Argentina
Colombia

Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global ovarian cancer drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Ovarian Cancer Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Ovarian Cancer Drugs Market

4. Voice of Customer

5. Clinical Trial Analysis

6. Patent Analysis

7. Global Ovarian Cancer Drugs Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others)

7.2.2. By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor)

7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

7.2.4. By Company (2021)

7.2.5. By Region

7.3. Market Map

8. North America Ovarian Cancer Drugs Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Drug Class

8.2.2. By Tumor Type

8.2.3. By Distribution Channel

8.2.4. By Country

8.3. North America: Country Analysis

8.3.1. United States Ovarian Cancer Drugs Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Drug Class

8.3.1.2.2. By Tumor Type

8.3.1.2.3. By Distribution Channel

8.3.2. Mexico Ovarian Cancer Drugs Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Drug Class

8.3.2.2.2. By Tumor Type

8.3.2.2.3. By Distribution Channel

8.3.3. Canada Ovarian Cancer Drugs Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Drug Class

8.3.3.2.2. By Tumor Type

8.3.3.2.3. By Distribution Channel

9. Europe Ovarian Cancer Drugs Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Drug Class

9.2.2. By Tumor Type

9.2.3. By Distribution Channel

9.2.4. By Country

9.3. Europe: Country Analysis

9.3.1. France Ovarian Cancer Drugs Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Drug Class

9.3.1.2.2. By Tumor Type

9.3.1.2.3. By Distribution Channel

9.3.2. Germany Ovarian Cancer Drugs Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Drug Class

9.3.2.2.2. By Tumor Type

9.3.2.2.3. By Distribution Channel

9.3.3. United Kingdom Ovarian Cancer Drugs Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Drug Class

9.3.3.2.2. By Tumor Type

9.3.3.2.3. By Distribution Channel

9.3.4. Italy Ovarian Cancer Drugs Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Drug Class

9.3.4.2.2. By Tumor Type

9.3.4.2.3. By Distribution Channel

9.3.5. Spain Ovarian Cancer Drugs Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Drug Class

9.3.5.2.2. By Tumor Type

9.3.5.2.3. By Distribution Channel

10. Asia-Pacific Ovarian Cancer Drugs Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Drug Class

10.2.2. By Tumor Type

10.2.3. By Distribution Channel

10.2.4. By Country

10.3. Asia-Pacific: Country Analysis

10.3.1. China Ovarian Cancer Drugs Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Drug Class

10.3.1.2.2. By Tumor Type

10.3.1.2.3. By Distribution Channel

10.3.2. India Ovarian Cancer Drugs Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Drug Class

10.3.2.2.2. By Tumor Type

10.3.2.2.3. By Distribution Channel

10.3.3. Japan Ovarian Cancer Drugs Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Drug Class

10.3.3.2.2. By Tumor Type

10.3.3.2.3. By Distribution Channel

10.3.4. South Korea Ovarian Cancer Drugs Market Outlook

10.3.4.1. Market Size & Forecast

10.3.4.1.1. By Value

10.3.4.2. Market Share & Forecast

10.3.4.2.1. By Drug Class

10.3.4.2.2. By Tumor Type

10.3.4.2.3. By Distribution Channel

10.3.5. Australia Ovarian Cancer Drugs Market Outlook

10.3.5.1. Market Size & Forecast

10.3.5.1.1. By Value

10.3.5.2. Market Share & Forecast

10.3.5.2.1. By Drug Class

10.3.5.2.2. By Tumor Type

10.3.5.2.3. By Distribution Channel

11. South America Ovarian Cancer Drugs Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Drug Class

11.2.2. By Tumor Type

11.2.3. By Distribution Channel

11.2.4. By Country

11.3. South America: Country Analysis

11.3.1. Brazil Ovarian Cancer Drugs Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Drug Class

11.3.1.2.2. By Tumor Type

11.3.1.2.3. By Distribution Channel

11.3.2. Argentina Ovarian Cancer Drugs Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Drug Class

11.3.2.2.2. By Tumor Type

11.3.2.2.3. By Distribution Channel

11.3.3. Colombia Ovarian Cancer Drugs Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Drug Class

11.3.3.2.2. By Tumor Type

11.3.3.2.3. By Distribution Channel

12. Middle East and Africa Ovarian Cancer Drugs Market Outlook

12.1. Market Size & Forecast

12.1.1. By Value

12.2. Market Share & Forecast

12.2.1. By Drug Class

12.2.2. By Tumor Type

12.2.3. By Distribution Channel

12.2.4. By Country

12.3. MEA: Country Analysis

12.3.1. South Africa Ovarian Cancer Drugs Market Outlook

12.3.1.1. Market Size & Forecast

12.3.1.1.1. By Value

12.3.1.2. Market Share & Forecast

12.3.1.2.1. By Drug Class

12.3.1.2.2. By Tumor Type

12.3.1.2.3. By Distribution Channel

12.3.2. Saudi Arabia Ovarian Cancer Drugs Market Outlook

12.3.2.1. Market Size & Forecast

12.3.2.1.1. By Value

12.3.2.2. Market Share & Forecast

12.3.2.2.1. By Drug Class

12.3.2.2.2. By Tumor Type

12.3.2.2.3. By Distribution Channel

12.3.3. UAE Ovarian Cancer Drugs Market Outlook

12.3.3.1. Market Size & Forecast

12.3.3.1.1. By Value

12.3.3.2. Market Share & Forecast

12.3.3.2.1. By Drug Class

12.3.3.2.2. By Tumor Type

12.3.3.2.3. By Distribution Channel

13. Market Dynamics

13.1. Drivers

13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape

15.1. AstraZeneca, Plc.

15.2. GlaxoSmithKline, Plc.

15.3. Merck & Co.

15.4. Clovis Oncology, Inc.

15.5. F. Hoffmann-La Roche AG

15.6. Bristol-Myers Squibb Co.

15.7. Eli Lilly and Company

15.8. Amgen Inc.

15.9. C.H. Boehringer Sohn Ko. KG

15.10. Novartis AG

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Ovarian Cancer Drugs Market?

Growing occurrence of the ovarian cancer, developments in the cancer therapies and others, the rising of the elderly population of women, among others are some of the factors driving the growth of global ovarian cancer drugs market.

Who are the top players operating in the Ovarian Cancer Drugs Market?

AstraZeneca, Plc., GlaxoSmithKline, Plc., Merck & Co., Clovis Oncology, Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Co., Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn Ko. KG, Novartis AG are the leading players operating in the global ovarian cancer drugs market.